This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-18 November 2022
Live In-Person Conference Delivered 15-18 NovemberAustria Center Vienna

Meena Meena, Ph.D.
Vice President of Bioanalytical, DMPK and Biomarker Development at Stoke Therapeutics


Meena is the vice president of bioanalytical, DMPK and biomarker development at Stoke Therapeutics. Meena brings 20 years of experience in nucleic acid therapeutics to Stoke. Prior to joining Stoke, Meena served as senior director of bioanalytical, pharmacology and biomarker development at Wave Life Sciences. During her eight-year tenure at Wave (formerly Ontorii) and as its first employee, Meena played a pivotal role in building Wave’s stereopure oligonucleotide chemistry platform and in guiding the clinical entry of three antisense programs. Earlier in her career, Meena worked at Alnylam Pharmaceuticals on siRNA chemistry and targeted siRNA delivery. Meena received her Ph.D. in chemistry with Dr. K.N. Ganesh at the National Chemical Laboratory in Pune, India, and did her postdoctoral research on nucleic acid analogs with Professor Larry W. McLaughlin at Boston College.

Agenda Sessions

  • Targeted Augmentation of Nuclear Gene Output (TANGO) Technology for Development of STK-001, for the Treatment of Dravet Syndrome